Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Atack

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Current Topics in Medicinal Chemistry|November 6, 2010
GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolyticsJohn R Atack
Expert Opinion on Investigational Drugs|June 2, 2005
The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolyticsJohn R Atack
Current Drug Targets. CNS and Neurological Disorders|July 23, 2003
Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding siteJohn R Atack
Advances in Pharmacology (San Diego, Calif.)|March 17, 2010
Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023John R Atack
Current Topics in Medicinal Chemistry|November 6, 2010
GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancementJohn R Atack
CNS Neuroscience & Therapeutics|May 17, 2008
GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancerJohn R Atack
Current Topics in Behavioral Neurosciences|February 11, 2011
GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolyticsJohn R Atack
Pharmacology & Therapeutics|September 23, 2009
Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IAJohn R Atack
Neurobiology of Aging|April 18, 2002
Inositol monophosphatase activity in normal, Down syndrome and dementia of the Alzheimer type CSFJohn R Atack, Mark B Schapiro
Biochemistry and Biophysics Reports|May 11, 2022
Exploring Calbindin-IMPase fusion proteins structure and activityJames W Noble, John R Atack
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Current Topics in Medicinal Chemistry|November 6, 2010
GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolyticsJohn R Atack
Expert Opinion on Investigational Drugs|June 2, 2005
The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolyticsJohn R Atack
Current Drug Targets. CNS and Neurological Disorders|July 23, 2003
Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding siteJohn R Atack
Advances in Pharmacology (San Diego, Calif.)|March 17, 2010
Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023John R Atack
Current Topics in Medicinal Chemistry|November 6, 2010
GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancementJohn R Atack
CNS Neuroscience & Therapeutics|May 17, 2008
GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancerJohn R Atack
Current Topics in Behavioral Neurosciences|February 11, 2011
GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolyticsJohn R Atack
Pharmacology & Therapeutics|September 23, 2009
Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IAJohn R Atack
Neurobiology of Aging|April 18, 2002
Inositol monophosphatase activity in normal, Down syndrome and dementia of the Alzheimer type CSFJohn R Atack, Mark B Schapiro
Biochemistry and Biophysics Reports|May 11, 2022
Exploring Calbindin-IMPase fusion proteins structure and activityJames W Noble, John R Atack
Pageof 10